¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Journal of enzyme inhibition."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • extracellular enzyme
    ¼¼Æ÷¿ÜÈ¿¼Ò
  • enzyme
    È¿¼Ò
  • enzyme activity
    È¿¼ÒȰ¼º, È¿¼ÒȰ¼ºµµ
  • enzyme assay
    È¿¼ÒÃøÁ¤
  • enzyme immunoassay
    È¿¼Ò¸é¿ªºÐ¼®(¹ý)
  • enzyme inhibitor
    È¿¼Ò¾ïÁ¦Á¦
  • enzyme labeled antibody
    È¿¼ÒÇ¥ÁöÇ×ü
  • enzyme labeling
    È¿¼ÒÇ¥Áö
  • enzyme modulator mediated immunoassay
    È¿¼ÒÁ¶Àý¸Å°³¸é¿ªºÐ¼®(¹ý)
  • enzyme precursor
    È¿¼ÒÀü±¸¹°Áú
  • enzyme-antibody conjugate
    È¿¼ÒÇ×üÁ¢ÇÕü
  • enzyme-antienzyme reaction
    È¿¼ÒÇ×È¿¼Ò¹ÝÀÀ
  • enzyme-linked immunoelectrotransfer blot
    È¿¼Ò°áÇո鿪ÀÌÀû¹ý, È¿¼Ò¿¬°ü¸é¿ªÀü±âÀü´Þ¹ý
  • enzyme-linked immunosorbent assay
    È¿¼Ò°áÇո鿪ÈíÂøÃøÁ¤(¹ý)
  • fibrinolytic enzyme
    ¼¶À¯¼Ò¿ëÇØÈ¿¼Ò, ÇǺ기¿ëÇØÈ¿¼Ò
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • enzyme-linked immunoelectrotransfer blot
    È¿¼Ò¸é¿ªÀÌÀû¹ý, È¿¼Ò¿¬°ü¸é¿ªÀü±âÀü´ÞÁ¡
  • constitutive enzyme
    ±âº»±¸¼ºÈ¿¼Ò
  • converting enzyme inhibitor
    Àüȯȿ¼Ò¾ïÁ¦Á¦
  • curdling enzyme
    ÀÀÀ¯È¿¼Ò
  • cytosolic enzyme
    ¼¼Æ÷ÁúÈ¿¼Ò
  • enzyme-antibody conjugate
    È¿¼ÒÇ×üÁ¢ÇÕü
  • debrancher enzyme
    °¡ÁöÁ¦°ÅÈ¿¼Ò
  • degumming enzyme
    ÇØ±³È¿¼Ò
  • diastatic enzyme
    ´çÈ­È¿¼Ò
  • digestive enzyme
    ¼ÒÈ­È¿¼Ò
  • enzyme
    È¿¼Ò
  • enzyme immunoassay
    È¿¼Ò¸é¿ªºÐ¼®(¹ý)
  • enzyme inhibitor
    È¿¼Ò¾ïÁ¦Á¦
  • enzyme labeling
    È¿¼ÒÇ¥Áö
  • enzyme precursor
    È¿¼ÒÀü±¸Ã¼
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • hemagglutination inhibition test =HIT
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
  • hemagglutination-inhibition (HI) test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • immunologic inhibition
    ¸é¿ªÇÐÀû ¾ïÁ¦.
  • indirect inhibition
    °£Á¢¾ïÁ¦.
  • inhibition
    ¾ïÁ¦,±ÝÁö
  • inhibition
    ¾ïÁ¦
  • inhibition
    ¾ïÁ¦, ÀúÁö
  • inhibition
    ¾ïÁ¦
  • inhibition
    ¾ïÁ¦.
  • inhibition reaction
    ¾ïÁ¦(¹ÝÀÀ), ÀúÁö(¹ÝÀÀ).
  • inhibition test
    ÀúÁö½ÃÇè(îÁò­ãËúÐ).
  • inhibition test
    ¾ïÁ¦½ÃÇè
  • inhibition test, agglutination
    ÀÀÁý¾ïÁ¦½ÃÇè, ÀÀÁýÀúÁö½ÃÇè
  • inhibition test, antiglobulin
    Çױ۷κҸ° ¾ïÁ¦½ÃÇè, Çױ۷κҸ° ÀúÁö½ÃÇè
  • inhibition test, fluorescence
    Çü±¤¾ïÁ¦½ÃÇè, Çü±¤ÀúÁö½ÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • inhibition
    ¾ïÁ¦
  • inhibition reaction
    ¾ïÁ¦(¹ÝÀÀ), ÀúÁö(¹ÝÀÀ).
  • inhibition test
    ¾ïÁ¦½ÃÇè
  • inhibition test
    ÀúÁö½ÃÇè(îÁò­ãËúÐ).
  • inhibition test, agglutination
    ÀÀÁý¾ïÁ¦½ÃÇè, ÀÀÁýÀúÁö½ÃÇè
  • inhibition test, antiglobulin
    Çױ۷κҸ° ¾ïÁ¦½ÃÇè, Çױ۷κҸ° ÀúÁö½ÃÇè
  • inhibition test, fluorescence
    Çü±¤¾ïÁ¦½ÃÇè, Çü±¤ÀúÁö½ÃÇè
  • inhibition test, hemagglutination
    Ç÷±¸ÀÀÁý ¾ïÁ¦½ÃÇè, Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • inhibition test, migration
    À¯ÁÖ¾ïÁ¦½ÃÇè, À¯ÁÖÀúÁö½ÃÇè
  • inhibition zone
    ¾ïÁ¦´ë(åäð¤Óá).
  • inhibition(-tory) factor, macrophage migration
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ
  • inhibition, allogeneic
    µ¿Á¾ÀÌÇü¾ïÁ¦
  • inhibition, contact
    Á¢Ã˼º Áõ½Ä¾ïÁ¦
  • inhibition, fertility
    FÀÎÀÚ Àü´ÞÀúÁö, ¼öÅÂÀÎÀÚ Àü´ÞÀúÁö
  • interal inhibition
    Ãø¹æ¾ïÁ¦(ö°Û°åäð¤).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • acyl enzyme
    ¾Æ½ÇÈ¿¼Ò(ý£áÈ)
  • acyl enzyme intermediates
    ¾Æ½ÇÈ¿¼Ò Áß°£Ã¼(ñéÊàô÷)
  • adaptive enzyme
    ÀûÀÀÈ¿¼Ò(îêëëý£áÈ)
  • alteration enzyme
    º¯ÇüÈ¿¼Ò(ܨúþý£áÈ)
  • ambiquitous enzyme
    ¾çÁ¸È¿¼Ò(å»ðíý£áÈ)
  • amino acid activating enzyme
    ¾Æ¹Ì³ë»ê(ß«) Ȱ¼ºÈ­(üÀàõûù) È¿¼Ò(ý£áÈ)
  • amplifier enzyme
    ÁõÆøÈ¿¼Ò(ñòøëý£áÈ)
  • analogous enzyme variants
    À¯»çÈ¿¼Ò º¯ÀÌÇü(×¾ÞÄý£áÈܨì¶úþ)
  • anti-enzyme
    Ç×È¿¼Ò(ù÷ý£áÈ)Ç×ü(ù÷ô÷)
  • antitumor enzyme
    Ç×Á¾¾ç È¿¼Ò(ù÷ðþåËý£áÈ)
  • auxilliary enzyme
    º¸Á¶È¿¼Ò (ÜÍð¾ý£áÈ)
  • basal enzyme
    ±âÀúÈ¿¼Ò(Ðñî¼ý£áÈ)
  • bound enzyme
    °áÇÕÈ¿¼Ò(ý£áÈ)
  • branching enzyme
    "ºÐÁöÈ¿¼Ò(ÝÂò«ý£áÈ), °¡ÁöÄ¡±â È¿¼Ò(ý£áÈ)"
  • breakage-reunion enzyme
    Àý´ÜÀç°áÇÕ È¿¼Ò(ï·Ó¨î¢Ì¿ùêý£áÈ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
MIF   1) Mllerian Inhibiting Factor
  2) Migrating Inhibition Factor
TBII TSH Binding Inhibiting(= Inhibition) Immunoglobulin
AGPI agar gel precipitin inhibition
CFI chemotactic-factor inactivator; closed-clenched fist injury; color flow imaging; complement fixation...
CI cardiac index; cardiac insufficiency; cell immunity; cell inhibition; cephalic index; cerebral infar...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
IOR Inhibition of return
ICI Intracortical inhibition
LI Latent Inhibition
LMI Leucocyte Migration Inhibition
LMIT Leucocyte Migration Inhibition Test
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • periplasmic enzyme
    ¿øÇüÁú¸· ÁÖÀ§ °ø°£ È¿¼Ò
  • phosphorylating enzyme
    ÀλêÈ­ È¿¼Ò
  • proteolytic enzyme
    ´Ü¹é ºÐÇØ È¿¼Ò
    ´Ü¹é ºÐÇØ¸¦ ÃËÁøÇÏ´Â È¿¼Ò.
  • Q enzyme
    Å¥ È¿¼Ò
    Æ÷µµ´ç-1-ÀλêÀÇ 1,6-C¿¡ ÀÛ¿ëÇÏ¿© À̰ÍÀ» ÁßÈ­½ÃŰ´Â È¿¼Ò.
  • rate-limiting enzyme
    ¼Óµµ Á¶Àý È¿¼Ò
  • receptor destroying enzyme
    ¼ö¿ëü ÆÄ±« È¿¼Ò
    ¼ö¿ëü¸¦ ÆÄ±«ÇÏ¿© ÀûÇ÷±¸ÀÇ ¹ÙÀÌ·¯½º ¿ëÇ÷¿¡ ´ëÇÑ °¨¼ö¼ºÀ» ÀÒ¾î¹ö¸®°Ô ÇÏ´Â È¿¼Ò.
  • splitting enzyme
    ºÐÇÒ È¿¼Ò
  • Z-enzyme
    ÁîÀÌ È¿¼Ò
    º£Å¸-¾Æ¹Ð¶óÁ¦¿Í Çù·ÂÇÏ¿© ¾Æ¹Ð·ÎÁ¦ÀÇ ¿ÏÀü ºÐÇØ¸¦ ÀÏÀ¸Å²´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
amino acid activating enzyme <enzyme> Enzymes catalyzing the formation of a specific aminoacyl-tRNA from an amino acid and adenosine 5'-triphosphate with the concomitant formation of adenosine 5'-monophosphate and pyrophosphate.
Synonym: amino acid activating enzyme, aminoacyl-tRNA ligases.
(05 Mar 2000)
angiotensin-converting enzyme <enzyme> This hydrolase enzyme cleaves the decapeptide angiotensin I (biologically inactive) to form active angiotensin II by angiotensin-converting enzyme which removes a dipeptide (histidylleucine) from angiotensin I.
Angiotensin II causes contraction of vascular smooth muscle and thus raises blood pressure and stimulates aldosterone release from the adrenal glands. Angiotensin is finally broken down by angiotensinases.
Elevations in angiotensin converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy. The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels).
Drugs that inhibit ACE are used to treat hypertension and congestive heart failure.
See: angiotensin-converting enzyme inhibitor
Acronym: ACE
(12 Aug 2000)
angiotensin-converting enzyme inhibitor <pharmacology> A class of drugs used in the treatment of hypertension and heart failure.
They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
(14 Aug 2000)
angiotensin-converting enzyme secretase <enzyme> Converts ace from a membrane-bound to a soluble form; not inhibited by thiol, serine or acid enzyme inhibitor but is inhibited by edta and 1,10-phenanthroline
Registry number: EC 3.4.99.-
Synonym: ace secretase
(26 Jun 1999)
Antibody Directed Enzyme Prodrug Therapy <pharmacology> A method for targeting a drug to a specific tissue, in which the targeting agent and the drug are administered separately.
The drug is designed to be inactive (a prodrug) until it is converted by an enzyme, which is the targeting agent. The enzyme is coupled to an antibody that directs it to the tissue of interest. When the enzyme arrives at the tissue, the prodrug is activated only at that site, sparing other tissues from potentially toxic side effects.
Acronym: ADEPT
(14 Nov 1997)
antitumour enzyme <enzyme> An enzyme that stimulates the degradation of a particular metabolite that cannot be synthesised by tumour cells, inhibits the synthesis of a metabolite needed by tumour cells, or inhibits tumour-specific DNA utilization; e.g., asparaginase.
(05 Mar 2000)
autolytic enzyme <enzyme> An enzyme capable of causing lysis of the cell forming it.
(05 Mar 2000)
beta-carotene cleavage enzyme <enzyme> An enzyme catalyzing the reaction of beta-carotene plus O2 producing two retinals.
Synonym: beta-carotene cleavage enzyme, carotenase, carotinase.
(05 Mar 2000)
branching enzyme 1,4-alpha-d-glucan branching enzyme
cardiac enzyme <biochemistry> A group of enzymes found normally in heart tissue. Cardiac enzymes are released into the blood stream in increased concentration when the heart muscle becomes damaged.
Examples include SGOT, CPK-MB and LDH.
(27 Sep 1997)
pancreatic enzyme <biochemistry> One of the proteins made by the pancreas that aid digestion of fats, carbohydrates and proteins.
(09 Oct 1997)
malate-condensing enzyme <enzyme> An important enzyme in the glyoxylic acid cycle which reversibly catalyses the synthesis of l-malate from acetyl-CoA and glyoxylate.
Chemical name: L-Malate glyoxylate-lyase (CoA-acetylating)
Registry number: EC 4.1.3.2
(12 Dec 1998)
malic enzyme <enzyme> An enzyme that catalyses the conversion of (s)-malate and NAD+ to oxaloacetate and NADH.
Chemical name: (S)-Malate:NAD+ oxidoreductase
Registry number: EC 1.1.1.37
(12 Dec 1998)
pantoate-activating enzyme pantothenate synthetase
marker enzyme <enzyme> An enzyme that is used to identify a specific cell type, cell organelle, or cell component.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á